Trial
NCT00823979
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Pfizer
Collaborators
—
Condition
HIV-1
Intervention
UK-453,061 Dose 1
Why stopped
See termination reason in detailed description.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-12-04